<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2014-398-404</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-1961</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Уровень цитокинов у больных ревматоидным артритом: связь с поражением легких</article-title><trans-title-group xml:lang="en"><trans-title>CYTOKINE LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN ASSOCIATION WITH LUNG INJURY</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бестаев</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bestaev</surname><given-names>D. V.</given-names></name></name-alternatives><email xlink:type="simple">davidbestaev@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новиков</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikov</surname><given-names>A. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Александрова</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Aleksandrova</surname><given-names>E. N.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Божьева</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bozhyeva</surname><given-names>L. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Глухова</surname><given-names>С. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Glukhova</surname><given-names>S. I.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Насонов</surname><given-names>Н. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Nasonov</surname><given-names>E. L.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>02</day><month>09</month><year>2014</year></pub-date><volume>52</volume><issue>4</issue><fpage>398</fpage><lpage>404</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бестаев Д.В., Новиков А.А., Александрова Е.Н., Божьева Л.А., Глухова С.И., Насонов Н.С., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Бестаев Д.В., Новиков А.А., Александрова Е.Н., Божьева Л.А., Глухова С.И., Насонов Н.С.</copyright-holder><copyright-holder xml:lang="en">Bestaev D.V., Novikov A.A., Aleksandrova E.N., Bozhyeva L.A., Glukhova S.I., Nasonov E.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/1961">https://rsp.mediar-press.net/rsp/article/view/1961</self-uri><abstract><p>В основе патогенеза ревматоидного артрита (РА) лежит дисбаланс между продукцией провоспалительных и противовоспалительных цитокинов, который может способствовать развитию системных проявлений, в частности, интерстициального поражения легких (ИПЛ).</p><p>Целью исследования явилось изучение концентрации цитокинов у больных РА с ИПЛ и без него.</p><sec><title>Материал и методы</title><p>Материал и методы. В исследование было включено три группы. В 1-ю вошли 20 больных РА с ИПЛ, во 2-ю – 30 пациентов с РА без ИПЛ и в 3-ю – 28 здоровых доноров. Все пациенты с РА находились на стационарном лечение в НИИР им. В.А. Насоновой. Диагноз РА ставился на основании критериев Американской коллегии ревматологов (ACR) 1987 г. Концентрацию 27 цитокинов сыворотки крови определяли с помощью мультиплексной технологии хМAР на анализаторе Bio-Plex200 (Вio-Rad, США). Для выявления ИПЛ проводилась компьютерная томография легких на спиральном компьютерном томографе GE Light Speed VCT (с толщиной среза 0,65 мм).</p></sec><sec><title>Результаты</title><p>Результаты. Отмечалось достоверное повышение концентрации интерлейкина 5 (ИЛ5), ИЛ6, ИЛ7, ИЛ8, ИЛ9, ИЛ10, ИЛ12, ИЛ15, эотаксина, гранулоцитарного колониестимулирующего фактора, гранулоцитарно-макрофагального колониестимулирующего фактора, интерферона γ (ИФНγ), макрофагального белка воспаления 1β, тромбоцитарного фактора роста BB, RANTES, фактора некроза опухоли α у больных РА с ИПЛ и без ИПЛ по сравнению со здоровыми донорами. Концентрации ИЛ4 и ИФНγ-индуцибельного белка при РА с ИПЛ оказались выше, чем в других группах, однако эти различия достигали статистической достоверности только по сравнению со здоровыми донорами (р=0,04 и р=0,001 соответственно). У больных РА с ИПЛ выявлено значительное повышение уровней ИЛ10, ИФНγ по сравнению с РА без поражения легких и здоровыми донорами (р=0,008 и р=0,0003; р=0,0001 и р=0,0001 соответственно). При РА с ИПЛ отмечались более низкие концентрации васкулоэндотелиального фактора роста, чем у здоровых доноров (р=0,05).</p></sec><sec><title>Выводы</title><p>Выводы. У больных РА с ИПЛ отмечается преобладание Th2 иммунного ответа. Выявленная активация регуляторов «гуморального» антигенспецифического иммунного ответа: ИЛ4, ИЛ5, ИЛ6, ИЛ10, ИФНγ, обосновывает применение анти-В-клеточной терапии при данном варианте заболевания.</p></sec></abstract><trans-abstract xml:lang="en"><p>The basis for the pathogenesis of rheumatoid arthritis (RA) is an imbalance in the production of proinflammatory and anti-inflammatory cytokines, which may favor the development of systemic manifestations, interstitial lung injury (ILI) in particular.</p><sec><title>Objective</title><p>Objective: to study cytokine concentrations in RA patients with and without ILI.</p></sec><sec><title>Subjects and methods</title><p>Subjects and methods. The investigation enrolled three groups. Group 1 included 20 RA patients with ILI; Group 2 comprised 30 RA patients without ILI and Group 3 consisted of 28 healthy donors. All the RA inpatients were treated at the V.A. Nasonova Research Institute of Rheumatology. The diagnosis of RA was made on the basis of the 1987American College of Rheumatology (ACR) criteria. The serum concentrations of 27 cytokines were determined utilizing multiplex xMAP technology with a Bio-Plex200 analyzer (Bio-Rad, USA). Lung computed tomography (CT) with a GE Light Speed VCT spiral CT scanner (with a section thickness of 0.65 mm) was carried out to detect ILI.</p></sec><sec><title>Results</title><p>Results. As compared with the healthy donors, the RA patients with and without ILI were observed to have significantly elevated concentrations of interleukin 5 (IL-5), IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-15, eotaxin, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, interferon-γ (IFN-γ), macrophage inflammatory protein-1β, platelet-derived growth factor BB, RANTES, and tumor necrosis factor-α. In the RA patients with ILI, the concentrations of IL-4 and IFN-γ-inducible protein proved to be higher than in the othergroups; however, these differences reached statistical significance compared to only the healthy donors (p = 0.04 and p = 0.001, respectively). The RA patients with ILI were found to have a significant increase in IL-10 and IFN-γ levels as compared to those without ILI and the healthy donors (p = 0.008 and p = 0.0003; p = 0.0001 and p = 0.0001, respectively). Vascular endothelial growth factor concentrations were found to be lower in the RA patients with ILI than in the healthy donors (p = 0.05).</p></sec><sec><title>Conclusion</title><p>Conclusion. The RA patients with ILI show a predominance of a Th2 immune response. The found activation of humoral antigen-specific immune response regulators, such as IL-4, IL-5, IL-6, IL-10, and IFN-γ, substantiates the use of anti-B-cell therapy for this type of the disease.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ревматоидный артрит</kwd><kwd>интерстициальное поражение легких</kwd><kwd>цитокины</kwd><kwd>мультиплексный анализ.</kwd></kwd-group><kwd-group xml:lang="en"><kwd>rheumatoid arthritis</kwd><kwd>interstitial lung injury</kwd><kwd>cytokines</kwd><kwd>multiplex analysis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ. Ревматоидный артрит как общемедицинская проблема. Терапевт. 2004;(5):5–7. [Nasonov EL. Rheumatoid arthritis as all-medical problem. Terapevt. 2004;(5):5–7. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Насонов ЕЛ. Ревматоидный артрит как общемедицинская проблема. Терапевт. 2004;(5):5–7. [Nasonov EL. Rheumatoid arthritis as all-medical problem. Terapevt. 2004;(5):5–7. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Ревматология: Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. Москва: ГЭОТАР- Медиа; 2008. С. 290–331. [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Revmatologiya. Natsional'noe rukovodstvo [Rheumatology. National Guide]. Nasonov EL, Nasonova VA, editors. Moscow: GEOTAR-media; 2008. P. 290–331.]</mixed-citation><mixed-citation xml:lang="en">Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Ревматология: Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. Москва: ГЭОТАР- Медиа; 2008. С. 290–331. [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Revmatologiya. Natsional'noe rukovodstvo [Rheumatology. National Guide]. Nasonov EL, Nasonova VA, editors. Moscow: GEOTAR-media; 2008. P. 290–331.]</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, редактор. Ревматология: Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010. 752 c. [Nasonov EL, editor. Revmatologiya: Klinicheskie rekomendatsii [Rheumatology: Clinical recommendations]. Moscow: GEOTARMedia; 2010. 752 p.]</mixed-citation><mixed-citation xml:lang="en">Насонов ЕЛ, редактор. Ревматология: Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010. 752 c. [Nasonov EL, editor. Revmatologiya: Klinicheskie rekomendatsii [Rheumatology: Clinical recommendations]. Moscow: GEOTARMedia; 2010. 752 p.]</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ройт А, Бростофф Дж, Мейл Д. Иммунология. Москва: Мир; 2000. 230 c. [Royt A, Brostoff Dzh, Meyl D. Immunologiya [Immunology]. Moscow: Mir; 2000. 230 p.]</mixed-citation><mixed-citation xml:lang="en">Ройт А, Бростофф Дж, Мейл Д. Иммунология. Москва: Мир; 2000. 230 c. [Royt A, Brostoff Dzh, Meyl D. Immunologiya [Immunology]. Moscow: Mir; 2000. 230 p.]</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Brennan F, Mclnnes I. Evidence that cytokines play a role in rrheumatoid arthritis. J Clin Invest. 2008;118(11):3537–45. DOI: http://dx.doi.org/10.1172/JCI36389.</mixed-citation><mixed-citation xml:lang="en">Brennan F, Mclnnes I. Evidence that cytokines play a role in rrheumatoid arthritis. J Clin Invest. 2008;118(11):3537–45. DOI: http://dx.doi.org/10.1172/JCI36389.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kingsmore S. Multiplexed protein measurement:technologies and applications of protein and antibody arrays. Nat Rev Drug Discov. 2006;5(4):310–20. DOI: http://dx.doi.org/10.1038/nrd2006.</mixed-citation><mixed-citation xml:lang="en">Kingsmore S. Multiplexed protein measurement:technologies and applications of protein and antibody arrays. Nat Rev Drug Discov. 2006;5(4):310–20. DOI: http://dx.doi.org/10.1038/nrd2006.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Новиков АА, Александрова ЕН, Попкова ТВ и др. Роль мультиплексного анализа цитокинов в оценке эффективности ритуксимаба при лечении ревматоидного артрита. Научно-практическая ревматология. 2011;(5):51–7. [Novikov AA, Aleksandrova EN, Popkova TV, et al. Role of multiplex cytokine analysis in the evaluation of the efficacy of rituximab during treatment for rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2011;(5):51–7. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2011-1461.</mixed-citation><mixed-citation xml:lang="en">Новиков АА, Александрова ЕН, Попкова ТВ и др. Роль мультиплексного анализа цитокинов в оценке эффективности ритуксимаба при лечении ревматоидного артрита. Научно-практическая ревматология. 2011;(5):51–7. [Novikov AA, Aleksandrova EN, Popkova TV, et al. Role of multiplex cytokine analysis in the evaluation of the efficacy of rituximab during treatment for rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2011;(5):51–7. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2011-1461.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Carmona L, Gonzalez-Alvaro I, Balsa A, et al. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis. 2003;62(9):897–900. DOI: http://dx.doi.org/10.1136/ard.62.9.897.</mixed-citation><mixed-citation xml:lang="en">Carmona L, Gonzalez-Alvaro I, Balsa A, et al. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis. 2003;62(9):897–900. DOI: http://dx.doi.org/10.1136/ard.62.9.897.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bilgici A, Ulusoy H, Kuru O, et al. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int. 2005;25(6):429–35. DOI: http://dx.doi.org/10.1007/s00296-004-0472-y.</mixed-citation><mixed-citation xml:lang="en">Bilgici A, Ulusoy H, Kuru O, et al. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int. 2005;25(6):429–35. DOI: http://dx.doi.org/10.1007/s00296-004-0472-y.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127(6):2019–27. DOI: http://dx.doi.org/10.1378/chest.127.6.2019.</mixed-citation><mixed-citation xml:lang="en">Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127(6):2019–27. DOI: http://dx.doi.org/10.1378/chest.127.6.2019.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nannini C, Ryu JH, Matteson EL. Lung disease in rheumatoid arthritis. Curr Opin Rheumatol. 2008;20(3):340–46. DOI: 10.1097/BOR.0b013e3282f798ed.</mixed-citation><mixed-citation xml:lang="en">Nannini C, Ryu JH, Matteson EL. Lung disease in rheumatoid arthritis. Curr Opin Rheumatol. 2008;20(3):340–46. DOI: 10.1097/BOR.0b013e3282f798ed.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Thannickal VJ, Toews GB, White ES, et al. Mechanisms of pulmonary fibrosis. Annu Rev Med. 2004;(55):395–417. DOI: http://dx.doi.org/10.1146/annurev.med.55.091902.103810.</mixed-citation><mixed-citation xml:lang="en">Thannickal VJ, Toews GB, White ES, et al. Mechanisms of pulmonary fibrosis. Annu Rev Med. 2004;(55):395–417. DOI: http://dx.doi.org/10.1146/annurev.med.55.091902.103810.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bringardner BD, Baran CP, Eubank TD, Marsh CB. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal. 2008;10(2):287–301. DOI:http://dx.doi.org/10.1089/ars.2007.1897.</mixed-citation><mixed-citation xml:lang="en">Bringardner BD, Baran CP, Eubank TD, Marsh CB. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal. 2008;10(2):287–301. DOI:http://dx.doi.org/10.1089/ars.2007.1897.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Thavarajah K, Wu P, Rhew EJ, et al. Pulmonary complications of tumor necrosis factor-targeted therapy. Respir Med. 2009;103(5):661–9. DOI: 10.1016/j.rmed.2009.01.002. Epub 2009 Feb 7.</mixed-citation><mixed-citation xml:lang="en">Thavarajah K, Wu P, Rhew EJ, et al. Pulmonary complications of tumor necrosis factor-targeted therapy. Respir Med. 2009;103(5):661–9. DOI: 10.1016/j.rmed.2009.01.002. Epub 2009 Feb 7.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lappalainen U, Whitsett JA, Wert SE, et al. Interleukin-1beta causes pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung. Am J Respir Cell Mol Biol. 2005;32(4):311–8. DOI: http://dx.doi.org/10.1165/rcmb.2004-0309OC.</mixed-citation><mixed-citation xml:lang="en">Lappalainen U, Whitsett JA, Wert SE, et al. Interleukin-1beta causes pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung. Am J Respir Cell Mol Biol. 2005;32(4):311–8. DOI: http://dx.doi.org/10.1165/rcmb.2004-0309OC.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA. 2007;104:11002–7. DOI: http://dx.doi.org/10.1073/pnas.0704421104.</mixed-citation><mixed-citation xml:lang="en">Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA. 2007;104:11002–7. DOI: http://dx.doi.org/10.1073/pnas.0704421104.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004;4(8):583–94. DOI:http://dx.doi.org/10.1038/nri1412.</mixed-citation><mixed-citation xml:lang="en">Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004;4(8):583–94. DOI:http://dx.doi.org/10.1038/nri1412.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta, converting enzyme. Ann NY Acad Sci. 1998;29(856):1–11. DOI: http://dx.doi.org/10.1111/j.1749-6632.1998.tb08307.x.</mixed-citation><mixed-citation xml:lang="en">Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta, converting enzyme. Ann NY Acad Sci. 1998;29(856):1–11. DOI: http://dx.doi.org/10.1111/j.1749-6632.1998.tb08307.x.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Hom JT, Bendele AM, Carlson DG. In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice. J Immunol. 1998;141(3):834–4.</mixed-citation><mixed-citation xml:lang="en">Hom JT, Bendele AM, Carlson DG. In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice. J Immunol. 1998;141(3):834–4.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Fulkerson PC, Fischetti CA, Rothenberg ME. Eosinophils and CCR3 regulate interleukin-13 transgene-induced pulmonary remodeling. Am J Pathol. 2006;169(6):2117–26. DOI: http://dx.doi.org/10.2353/ajpath.2006.060617.</mixed-citation><mixed-citation xml:lang="en">Fulkerson PC, Fischetti CA, Rothenberg ME. Eosinophils and CCR3 regulate interleukin-13 transgene-induced pulmonary remodeling. Am J Pathol. 2006;169(6):2117–26. DOI: http://dx.doi.org/10.2353/ajpath.2006.060617.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ramalingam TR, Pesce JT, Sheikh F, et al. Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain. Nat. Immunol. 2008;9:25–33. DOI: http://dx.doi.org/10.1038/ni1544.</mixed-citation><mixed-citation xml:lang="en">Ramalingam TR, Pesce JT, Sheikh F, et al. Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain. Nat. Immunol. 2008;9:25–33. DOI: http://dx.doi.org/10.1038/ni1544.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Lupardus PJ, Birnbaum ME, Garcia KC. Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2. Structure. 2010;18(3):332–42. DOI: 10.1016/j.str.2010.01.003.</mixed-citation><mixed-citation xml:lang="en">Lupardus PJ, Birnbaum ME, Garcia KC. Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2. Structure. 2010;18(3):332–42. DOI: 10.1016/j.str.2010.01.003.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Wilson MS, Elnekave E, Mentink-Kane M, et al. IL-13Ralpha2 and IL-10 coordinately suppress airway inflammation, airwayhyperreactivity, and fibrosis in mice. J Clin Invest. 2007;117(10):2941–51. DOI:http://dx.doi.org/10.1172/JCI31546.</mixed-citation><mixed-citation xml:lang="en">Wilson MS, Elnekave E, Mentink-Kane M, et al. IL-13Ralpha2 and IL-10 coordinately suppress airway inflammation, airwayhyperreactivity, and fibrosis in mice. J Clin Invest. 2007;117(10):2941–51. DOI:http://dx.doi.org/10.1172/JCI31546.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Strieter RM, Belperio JA, Keane MP. CXC chemokines in vascular remodeling related to pulmonary fibrosis. Am J Respir Cell Mol Biol. 2003;29(3 Suppl):S67–9.</mixed-citation><mixed-citation xml:lang="en">Strieter RM, Belperio JA, Keane MP. CXC chemokines in vascular remodeling related to pulmonary fibrosis. Am J Respir Cell Mol Biol. 2003;29(3 Suppl):S67–9.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Simonian PL, Roark CL, Wehrmann F, et al. Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. J Immunol. 2009;182(1):657–65. DOI: http://dx.doi.org/10.4049/jimmunol.182.1.657.</mixed-citation><mixed-citation xml:lang="en">Simonian PL, Roark CL, Wehrmann F, et al. Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. J Immunol. 2009;182(1):657–65. DOI: http://dx.doi.org/10.4049/jimmunol.182.1.657.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Wilson MS, Madala SK, Ramalingam TR, et al. Bleomycin and IL-1β-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med. 2010;207(3):535–52. DOI: 10.1084/jem.20092121. Epub 2010 Feb 22.</mixed-citation><mixed-citation xml:lang="en">Wilson MS, Madala SK, Ramalingam TR, et al. Bleomycin and IL-1β-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med. 2010;207(3):535–52. DOI: 10.1084/jem.20092121. Epub 2010 Feb 22.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Brodlie M, McKean MC, Johnson GE, et al. Raised interleukin-17 is immunolocalised to neutrophils in cystic fibrosis lung disease. Eur Respir J. 2011;37(6):1378–85. DOI: 10.1183/09031936.00067110. Epub 2010 Nov 25.</mixed-citation><mixed-citation xml:lang="en">Brodlie M, McKean MC, Johnson GE, et al. Raised interleukin-17 is immunolocalised to neutrophils in cystic fibrosis lung disease. Eur Respir J. 2011;37(6):1378–85. DOI: 10.1183/09031936.00067110. Epub 2010 Nov 25.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Hariyawasam HH, Nicholson GC, Tan AJ, et al. Effects of Anti-IL-13 (Novartis QAX576) on Inflammatory Responses Following Nasal Allergen Challenge (NAC). Am J Respir Crit Care Med. 2009;179:A3642.</mixed-citation><mixed-citation xml:lang="en">Hariyawasam HH, Nicholson GC, Tan AJ, et al. Effects of Anti-IL-13 (Novartis QAX576) on Inflammatory Responses Following Nasal Allergen Challenge (NAC). Am J Respir Crit Care Med. 2009;179:A3642.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Dayer J, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985;162(6):2163–8. DOI: http://dx.doi.org/10.1084/jem.162.6.2163.</mixed-citation><mixed-citation xml:lang="en">Dayer J, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985;162(6):2163–8. DOI: http://dx.doi.org/10.1084/jem.162.6.2163.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Bazzoni E, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334(2):1717–25.</mixed-citation><mixed-citation xml:lang="en">Bazzoni E, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334(2):1717–25.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
